{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sultan D"],"funding":["BLRD VA","NHLBI","Foundation for Barnes-Jewish Hospital","Cystic Fibrosis Foundation","NIAID NIH HHS","NHLBI NIH HHS","National Institutes of Health","NIAID","U.S. Department of Veterans Affairs","Veterans Health Administration Biomedical Laboratory Research and Development"],"pagination":["102416"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8684599"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36"],"pubmed_abstract":["The development of atherosclerosis therapy is hampered by the lack of molecular imaging tools to identify the relevant biomarkers and determine the dynamic variation in vivo. Here, we show that a chemokine receptor 2 (CCR2) targeted gold nanocluster conjugated with extracellular loop 1 inverso peptide (AuNC-ECL1i) determines the initiation, progression and regression of atherosclerosis in apolipoprotein E knock-out (ApoE<sup>-/-</sup>) mouse models. The CCR2 targeted <sup>64</sup>Cu-AuNC-ECL1i reveals sensitive detection of early atherosclerotic lesions and progression of plaques in ApoE<sup>-/-</sup> mice. CCR2 targeting specificity was confirmed by the competitive receptor blocking studies. In a mouse model of aortic arch transplantation, <sup>64</sup>Cu-AuNC-ECL1i accurately detects the regression of plaques. Human atherosclerotic tissues show high expression of CCR2 related to the status of the disease. This study confirms CCR2 as a useful marker for atherosclerosis and points to the potential of <sup>64</sup>Cu-AuNC-ECL1i as a targeted molecular imaging probe for future clinical translation."],"journal":["Nanomedicine : nanotechnology, biology, and medicine"],"pubmed_title":["Assessment of ultrasmall nanocluster for early and accurate detection of atherosclerosis using positron emission tomography/computed tomography."],"pmcid":["PMC8684599"],"funding_grant_id":["R01HL153436","R01HL094601","I01 BX002730","R01HL151078","R01 HL151078","P01 AI116501","R01 HL153436","R01 HL094601","R35 HL145212","1I01BX002730"],"pubmed_authors":["Li W","Liu Y","Heo GS","Luehmann HP","Kreisel D","Sultan D","Detering L"],"additional_accession":[]},"is_claimable":false,"name":"Assessment of ultrasmall nanocluster for early and accurate detection of atherosclerosis using positron emission tomography/computed tomography.","description":"The development of atherosclerosis therapy is hampered by the lack of molecular imaging tools to identify the relevant biomarkers and determine the dynamic variation in vivo. Here, we show that a chemokine receptor 2 (CCR2) targeted gold nanocluster conjugated with extracellular loop 1 inverso peptide (AuNC-ECL1i) determines the initiation, progression and regression of atherosclerosis in apolipoprotein E knock-out (ApoE<sup>-/-</sup>) mouse models. The CCR2 targeted <sup>64</sup>Cu-AuNC-ECL1i reveals sensitive detection of early atherosclerotic lesions and progression of plaques in ApoE<sup>-/-</sup> mice. CCR2 targeting specificity was confirmed by the competitive receptor blocking studies. In a mouse model of aortic arch transplantation, <sup>64</sup>Cu-AuNC-ECL1i accurately detects the regression of plaques. Human atherosclerotic tissues show high expression of CCR2 related to the status of the disease. This study confirms CCR2 as a useful marker for atherosclerosis and points to the potential of <sup>64</sup>Cu-AuNC-ECL1i as a targeted molecular imaging probe for future clinical translation.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-05T16:11:29.436Z","creation":"2025-04-05T16:11:29.436Z"},"accession":"S-EPMC8684599","cross_references":{"pubmed":["34147662"],"doi":["10.1016/j.nano.2021.102416"]}}